Editorial

                     


November 13, 2012

Henry Schein Boosts Share Buyback Plan by $300 Million
Filed under: Equities Editor's Desk,Healthcare — Andrew Klips @ 7:00 am

Henry Schein Boosts Share Buyback Plan by $300 MillionHenry Schein Inc. (HSIC) said Tuesday morning that its board of directors has approved increasing its $200 – $300 million-share buyback program announced in April by an additional $300 million.  Approximately $243 million worth of shares of the original plan (3.2 million shares) have been bought-back already as part of the initial plan as the company executes its plan to try and build greater shareholder value.

At current prices around $77 per share, the additional plan represents about 4 percent of the 88.3 million shares outstanding as of September 29 of the world’s largest provider of health care products and services to office-based dental, medical and animal practitioners.

Shares will be purchased through negotiated transactions or through open market purchases, according to today’s corporate statement.

“Earlier this year we stated our intention to repurchase $200 million to $300 million annually in Henry Schein shares reflective of the strength in our balance sheet and our confidence in the long-term prospects of our business,” said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein.

On November 7, the Melville, New York-based company said that net sales for the third quarter increased 5.7 percent to $2.2 billion, despite a 3.2 percent decline related to an unfavorable foreign currency exchange.  Net income rose 5.2 percent from the year prior quarter to $96.8 million, or $1.08 per diluted share.  Analysts were expecting earnings of $1.07 per share and revenue of $2.24 billion.

Shares of HSIC closed Monday at $77.07, up about 20 percent for 2012.  Interesting, traders have kept shares rangebound for about six months between a support level around $73 per share and 52-week highs at about $80, providing 10 percent swings for investors focused on those parameters. 

Comments

comments


About Andrew Klips

Andrew Klips became enraptured with the markets as a teenager and has been an active trader on a daily basis for more than a decade. Specializing in technical analysis, he is an avid player of stock charts making technical bottoms mixed with a particular affinity for the fundamentals of biotechnology companies. (read more about Andrew Klips)...
| |

Comments

No Comments »

RSS feed for comments on this post. TrackBack URL

Leave a comment

 

Sector News



Market Overview

Symbol Last Change % Change
DJIA15,354.40121.180.80
NASDAQ3,498.9733.722270.97
S&P 500 EOD1,666.0715.600.95
10yr Trsy19.490.583.07
Data is delayed 20 mins/EOD

Uncommon Wisdom with Fisher Investments

Fisher Investments
Japanese policymakers largely understand what their Chinese counterparts don’t—encouraging private firms to invest more and as they see fit is the best way to goad sustainable economic growth.

Behind the Frontlines with Mauldin Economics

John Mauldin
There is a great deal of discussion about Europe's economic crisis and finding a way to return to the lost promise of the European Union. But what was that promise?

Richard Suttmeier of ValuEngine

Richard Suttmeier
The daily chart for AMD shows overbought momentum with the stock above its 21-day, 50-day and 200-day simple moving averages.